-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-05-28
SOLV:NYE- (USD)
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 72.63Change
+0.10 (+0.14)%Market Cap
USD 12.82BVolume
0.99M
N/A
Verdict
Values as of: 2025-05-28
COMMON STOCK | Medical Instruments & Supplies |
Last Closing
USD 72.63Change
+0.10 (+0.14)%Market Cap
USD 12.82BVolume
0.99MN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
BDX | Becton Dickinson and Company |
+0.81 (+0.47%) |
USD 50.27B |
ALC | Alcon AG |
+0.97 (+1.14%) |
USD 44.43B |
RMD | ResMed Inc |
+0.36 (+0.15%) |
USD 36.90B |
BAX | Baxter International Inc |
+0.12 (+0.39%) |
USD 16.25B |
ATR | AptarGroup Inc |
+0.93 (+0.59%) |
USD 10.37B |
AVTR | Avantor Inc |
+0.01 (+0.08%) |
USD 9.14B |
STVN | Stevanato Group SpA |
-0.31 (-1.34%) |
USD 6.09B |
TFX | Teleflex Incorporated |
+1.44 (+1.19%) |
USD 5.34B |
BLCO | Bausch + Lomb Corp |
+0.26 (+2.27%) |
USD 4.00B |
WRBY | Warby Parker Inc |
+0.68 (+3.39%) |
USD 2.41B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
HLTH:AU | VanEck Global Healthcare .. | 2.45 % | 0.00 % |
+0.02 (+0.17%) |
USD 0.06B |
CSD | Invesco S&P Spin-Off ETF | 0.00 % | 1.16 % |
-0.09 (0.17%) |
N/A |
CSD | Invesco S&P Spin-Off ETF | 0.00 % | 0.61 % |
-0.09 (0.17%) |
N/A |
Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 9.95% | 100% | F | 84% | B | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 9.95% | 100% | F | 84% | B | ||
Trailing 12 Months | |||||||
Capital Gain | 21.62% | 95% | A | 86% | B+ | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 21.62% | 95% | A | 84% | B | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 0.93% | 47% | F | 41% | F | ||
Dividend Return | 0.93% | 47% | F | 29% | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 3.63% | 100% | F | 95% | A | ||
Risk Adjusted Return | 25.54% | 84% | B | 44% | F | ||
Market Capitalization | 12.82B | 75% | C | 88% | B+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector